查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球類毒素疫苗市場
市場調查報告書
商品編碼
1272775

2023-2030 年全球類毒素疫苗市場

Global Toxoid Vaccine Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球類毒素疫苗市場預計到 2022 年將達到 55.856 億美元，到 2030 年將達到 82.672 億美元。 預計該市場在預測期內（2023-2030 年）的複合年增長率為 5.1%。 主要市場參與者的存在，佔亞太地區類毒素疫苗市場份額的大部分，確保該地區以高複合年增長率增長。

例如，2022 年 10 月，印度領先的生物技術公司之一 Panacea Biotec 與聯合國兒童基金會簽署了一項協議，供應經世衛組織預審的完整液體五價疫苗 Easyfive-TT (DTwP-HepB-Hib)。美國衛生組織 (PAHO) 長期供應獎，價值 1.273 億美元（約合 1,040 卡路裡的印度盧比）。

此外，2022 年 9 月，在 Covid 疫苗取得成功後，印度血清研究所將專注於白喉、百日咳和破傷風 (Tdap) 疫苗設計。 該公司已將 2-3 期臨床試驗數據提交給印度藥物管制委員會 (DCGI) 的專家小組，以批准生產該疫苗。 因此，數據表明，在整個預測期內，亞太地區的類毒素市場將以高複合年增長率增長。

全球類毒素疫苗市場是針對使用類毒素作為抗原以針對某些細菌性疾病（如破傷風）產生免疫反應的疫苗。 這種疫苗對於保護成人和 7 歲以上的兒童免受破傷風特別有效。

由於傳染病的流行、對疫苗接種益處的認識提高以及政府主導的旨在促進疫苗接種計劃的努力等多種因素，預計類毒素疫苗市場將大幅增長。. 此外，市場主要參與者正在進行的研發活動和新產品的推出預計將進一步推動全球類毒素疫苗市場的增長。

市場動態

政府資助的傳染病預防計劃的增加預計將推動全球類毒素疫苗市場的增長

針對類毒素疫苗的政府舉措，例如孕產婦、新生兒和新生兒破傷風根除 (MNTE) 計劃，在推動全球類毒素疫苗市場的增長方面發揮著關鍵作用。 孕產婦和新生兒破傷風 (MNT) 是一種危及生命的疾病，可由不潔分娩和臍帶護理做法引起。 MNTE 倡議旨在將 MNT 病例數量減少到如此低的水平，以至於該疾病不再是主要的公共衛生問題。

各國政府和世界衛生組織 (WHO) 等國際組織通過資助免疫計劃和公共衛生運動積極支持 MNTE 倡議。 由於這些努力，全球類毒素疫苗市場預計在預測期內將顯著增長。

全球類毒素疫苗市場增長可能因對這些疫苗的不同誘導過敏反應而面臨限制

破傷風類毒素疫苗的使用受到注射部位疼痛和發紅等局部反應以及發燒、疲勞和肌痛等全身反應的限制。 對疫苗的嚴重過敏反應很少見，但一小部分人可能會擔心。

此外，由於疫苗接種的普及，破傷風的發病率顯著下降，疫苗需求也隨之減少。 破傷風類毒素疫苗市場的特點是在佔有很大份額的合同市場和私人市場之間存在分歧。

COVID-19 影響分析

類毒素疫苗市場受到大流行的影響好壞參半。 對破傷風類毒素疫苗的需求一直穩定，因為它已被納入常規免疫接種，而對白喉類毒素疫苗的需求隨著世界許多地區白喉發病率的下降而下降。

儘管存在這種情況，但由於持續需要疫苗接種計劃來控制傳染病，全球類毒素疫苗市場預計將繼續穩步增長。. 預計大流行對市場的總體影響是溫和的。

俄烏衝突分析

全球類毒素疫苗市場並未受到俄羅斯和烏克蘭之間持續衝突的顯著影響。 因為大部分生產和分銷都位於衝突地區之外。 然而，據報導，該地區的衝突擾亂了供應鏈，並導致難以獲得包括疫苗在內的醫療用品。

此外，在一些地區，醫院和診所等醫療保健設施因衝突而遭到破壞或摧毀。 這使得難以為民眾提供必要的醫療保健服務，包括疫苗接種計劃。

內容

第 1 章研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按疾病分類
  • 按組成
  • 最終用戶
  • 按地區

第四章市場動態

  • 影響因素
    • 主持人
      • 政府資助的傳染病預防計劃的增加預計將推動全球類毒素疫苗市場的增長
    • 約束因素
      • 類毒素疫苗引起的過敏反應可能會限制全球類毒素疫苗市場的增長
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法律法規分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第7章疾病

  • 破傷風
  • 白喉
  • 百日咳

第八章行動

  • 白喉、破傷風、百日咳 (DtaP)
  • 白喉和破傷風 (DT)
  • 破傷風、白喉、百日咳 (Tdap)
  • 單價破傷風類毒素 (TT)
  • 破傷風和白喉 (Td)

第 9 章最終用戶

  • 醫院和診所
  • 政府機構
  • 其他

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 競爭場景
  • 市場定位/份額分析
  • 併購分析

第12章公司簡介

  • 賽諾菲公司
    • 公司概況
    • 產品組合和說明
    • 財務摘要
    • 主要發展狀況
  • Serum Institute of India Pvt. Ltd.
  • Panacea Biotec
  • Biological E Limited
  • GlaxoSmithKline
  • Merck & Co. Inc.
  • Astellas Pharma Inc.
  • Bharat Biotech
  • Dano Vaccines
  • Abbot

第13章 附錄

簡介目錄
Product Code: PH2169

Market Overview

The global toxoid vaccine market reached US$ 5,585.6 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 8,267.2 million by 2030. The market is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030). The presence of key market players holding the majority of the toxoid vaccine market share in the Asia-Pacific region ensures the growth of this region at a high CAGR rate.

For instance, in October 2022, Panacea Biotec, one of India's leading biotechnology companies, received long-term supply awards worth US$ 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for the supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib).

Moreover, in September 2022, after a successful run with its covid vaccine, the Serum Institute of India focused on designing a vaccine for Diphtheria, Pertussis, and Tetanus (Tdap). The company has presented its phase 2-3 clinical trial data to the Drugs Control General of India (DCGI)'s expert panel seeking permission to manufacture the vaccines. Thus, the data indicate that the Asia-Pacific toxoid market will grow at a high CAGR throughout the forecast period.

The global toxoid vaccine market is the market for vaccines that use toxoids as antigens to create an immune response against specific bacterial diseases, such as tetanus. This type of vaccine is particularly effective at providing protection against tetanus in adults and children aged seven years or older.

The market for toxoid vaccines is expected to grow at a significant rate due to several factors, including the rising prevalence of infectious diseases, increased awareness of the benefits of vaccination, and government-led initiatives aimed at promoting vaccination programs. In addition, ongoing research and development activities and new product launches by major players in the market are expected to further boost the growth of the global toxoid vaccine market.

Market Dynamics

The rising number of government-funded programs to prevent infectious diseases is expected to drive the growth of the global toxoid vaccine market

Government initiatives for toxoid vaccine, such as the Maternal and Neonatal Tetanus Elimination (MNTE) initiative, play a crucial role in driving the global toxoid vaccine market growth. Maternal and Neonatal Tetanus (MNT) is a life-threatening disease that can occur due to unclean deliveries and umbilical cord care practices. The MNTE initiative aims to reduce the number of MNT cases to such low levels that the disease is no longer a major public health problem.

Governments and international organizations, such as the World Health Organization (WHO), have been actively supporting the MNTE initiative by providing funding for immunization programs and public health campaigns. As a result of these initiatives, the global toxoid vaccine market is expected to grow significantly over the forecast period.

The global toxoid vaccine market growth may face constraints due to allergic reactions caused by these vaccines.

The use of the tetanus toxoid vaccine is limited by the occurrence of local reactions such as pain and redness at the site of injection, as well as systemic reactions like fever, fatigue, and muscle pain. Although severe allergic reactions to the vaccine are rare, they can be a concern for a small percentage of people.

Moreover, the incidence of tetanus has declined significantly due to widespread vaccination, resulting in a reduction in demand for the vaccine. The market for tetanus toxoid vaccine is characterized by a dichotomy between the contractual market, which holds a significant share, and the private market.

COVID-19 Impact Analysis

The toxoid vaccine market has experienced a somewhat mixed impact from the pandemic. While the demand for tetanus toxoid vaccines has remained stable due to their inclusion in routine immunization schedules, the demand for diphtheria toxoid vaccines has declined because of reduced diphtheria incidence in many areas worldwide.

Despite this, the global toxoid vaccine market is projected to continue growing at a steady pace because of the ongoing necessity for vaccination programs to manage infectious diseases. The pandemic's overall impact on the market is predicted to be moderately significant.

Russia-Ukraine Conflict Analysis

The global toxoid vaccine market has not been significantly affected by the ongoing conflict between Russia and Ukraine, as most of the production and distribution is situated outside the conflict zone. However, there have been reports of disruptions in supply chains and difficulties in accessing medical supplies, including vaccines, due to the conflict in the region.

Furthermore, the conflict has resulted in damage or destruction of healthcare facilities, such as hospitals and clinics, in some areas. This has made it challenging for the country to provide necessary healthcare services, including vaccination programs, to the population.

Segment Analysis

The global toxoid vaccine market is segmented based on disease, composition, end user, and region.

The diphtheria, tetanus, and pertussis (DtaP) segment is expected to hold the highest market share for the global toxoid vaccine market.

The Diphtheria, Tetanus, and Pertussis (DTaP) segment is expected to be the dominant segment in the global toxoid vaccine market, holding 44.2% of the market share over the forecast period. DTaP is a vaccine that helps children under the age of seven develop immunity against three deadly diseases caused by diphtheria, tetanus, and whooping cough (pertussis). The low cost of the vaccine, increasing tetanus cases, and its availability in low-resource economies such as Africa are driving the growth of the DTaP vaccine segment.

In the United States, there are currently seven licensed pediatric DTaP vaccines being used: Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, Quadracel, and Vaxelis. The growth of the DTaP vaccine segment during the forecast period is attributed to the increasing prevalence of diphtheria, tetanus, and pertussis, product launches, rising demand for combination vaccines, and high adoption of DTaP vaccines.

Geographical Analysis

The presence of major players to dominate the North America region.

The toxoid vaccine market is expected to grow significantly in North America region over the forecast period due to the presence of key market players who hold a major global toxoid market share. The market players have implemented various market strategies such as collaborations, disease launches, and acquisitions to expand their reach and increase their toxoid vaccine market share. It is predicted that North America will dominate the global toxoid vaccine market by acquiring around 2/5th of the market share.

For instance, in June 2022, GSK plc, a global pharmaceutical company, invested a significant amount of over US$1.2 billion in R&D to develop vaccines and medicines to prevent and treat various diseases, including malaria, tuberculosis, HIV, neglected tropical diseases, and diphtheria. All these factors indicate that North America is expected to remain the dominant region in the global toxoid vaccine market.

Competitive Landscape

The major global players in the market include Sanofi S.A., Serum Institute of India Pvt. Ltd., Panacea Biotec, Biological E Limited, GlaxoSmithKline, Merck & Co. Inc., Astellas Pharma Inc., Bharat Biotech, Dano Vaccines, and Abbott.

Why Purchase the Report?

  • To visualize the global toxoid vaccine- market segmentation based on disease, composition, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global toxoid vaccine market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global toxoid vaccine market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease
  • 3.2. Snippet by Composition
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising number of government-funded programs to prevent infectious diseases is expected to drive the growth of the global toxoid vaccine market
    • 4.1.2. Restraints
      • 4.1.2.1. The global toxoid vaccine market growth may face constraints due to allergic reaction caused by these vaccines
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 7.1.2. Market Attractiveness Index, By Disease
  • 7.2. Tetanus
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Diphtheria
  • 7.4. Pertussis

8. By Composition

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 8.1.2. Market Attractiveness Index, By Composition
  • 8.2. Diphtheria, Tetanus, and Pertussis (DtaP)
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diphtheria and Tetanus (DT)
  • 8.4. Tetanus, Diphtheria, and Pertussis (Tdap)
  • 8.5. Monovalent Tetanus Toxoid (TT)
  • 8.6. Tetanus and Diphtheria (Td)

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals And Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Government Organizations
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Sanofi S.A.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Serum Institute of India Pvt. Ltd.
  • 12.3. Panacea Biotec
  • 12.4. Biological E Limited
  • 12.5. GlaxoSmithKline
  • 12.6. Merck & Co. Inc.
  • 12.7. Astellas Pharma Inc.
  • 12.8. Bharat Biotech
  • 12.9. Dano Vaccines
  • 12.10. Abbot

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us